Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I

Hormone and Metabolic Research

Volumn 40, Issue 6, 2008, Pages 369-374

  Liefvendahl, E ^a   Arnqvist, H J ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cancer cell line; DNA synthesis; Receptors; Sarcoma cell line; Tyrosine kinase

Indexed keywords

DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INSULIN; INSULIN GLARGINE; INSULIN RECEPTOR; POLYPEPTIDE; RECEPTOR PROTEIN; RECOMBINANT HUMAN INSULIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; THYMIDINE; TRITIUM;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL STRAIN MCF 7; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MITOGENESIS; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CELL DIVISION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MITOGENS; OSTEOSARCOMA; RECEPTOR, IGF TYPE 1; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED;

EID: 47049123594     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1062739     Document Type: Article

References (29)

1. Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Leendert R Van. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005; 37: 702-707
2. Lindström T, Olsson P-O, Arnqvist HJ. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles. Scand J Clin Lab Invest 2000; 60: 341-347
3. Heise T, Nosek L, Rønn BB, Endahl L, Heinemarm L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620
4. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174-183
5. B32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997; 320: 259-265
6. Kurtzhals P, Schaffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005
7. Lammers R, Gray A, Schlessinger J, Ullrich A. Differential signalling potential of insulin- and IGF-1 -receptor cytoplasmic domains. EMBO J 1989; 8: 1369-1375
8. Blakesley VA, Scrimgeour A, Esposito D, Le Roith D. Signaling via the insulin-like growth factor-I receptor: Does it differ from insulin receptor signaling? Cytokine Growth Factor Rev 1996; 7: 153-159
9. Moxham CP, Duronio V. Jacobs S. Insulin-like growth factor I receptor β-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 1989; 264: 13238-13244
10. Bailyes EM, Navé BT, Soos MA, Orr SR, Hayward AC, Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 1997; 327: 209-215
11. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancergrowth and metastasis: overview and recent insights (Abstract). Endocr Rev 2007; 28: 20-47
12. Papa V, Gliozzo B, Clark GM, MacGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993; 53: 3736-3740
13. Pandini G, Vigneri R, Constantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID, Belfiore A. Insulin and insulin-like growth factor-I (IGF-1) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999; 5: 1935-1944
14. Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 2003; 34: 803-808
15. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J. Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and pros tate cancer risk: a prospective study. Science 1998; 279: 563-566
16. Hankinson SE, Willet WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 1998; 351: 1393-1396
17. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620-625
18. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999; 91: 151-156
19. Wu Y, Cui K, Miyoshi K, Henninghausen L, Green JE, Setser J, LeRoith D, Yakar S. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003; 63: 4384-4388
20. Hsing AW, Chua Jr S, Gao Y-T, Gentzschein E, Chang L, Deng J. Stanczyk FZ. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001; 93: 783-789
21. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20: 42-51
22. Saito K, Inoue S, Saito T, Kiso S, Ito N, Tamura S, Watanabe H, Takeda H, Misawa H, Togashi H, Matsuzawa Y, Kawata S. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002; 51: 100-104
23. Benyoucef S, Surinya KH, Hadaschik D, Siddle K. Characterisation of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domain and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem J 2007; 403: 603-613
24. 10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: Evidence for enhance interactions with the insulin-like growth factor-I receptor. Mol Carcinog 1997; 18: 19-25
25. Chisalita SI, Arnqvist HJ. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macro-vascular endothelial cells. Am J Physiol Endocrinol Metab 2004; 286: 896-901
26. Staiger K, Hennige AM, Staiger H, Häring H-U, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells Horm Metab Res 2007; 39: 65-67
27. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Häring HU. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 1998; 30: 123-129
28. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34
29. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002; 21: 171-179